Having successfully navigated the Humira patent cliff, AbbVie is poised for continued growth.

AbbVie has unveiled the first data from its $350 million obesity bet, with the amylin analog demonstrating weight loss of close to 10% after 12 weeks in one dose cohort.

AbbVie’s CEO Robert Michael is emerging from his sophomore year at the helm with $32.5 million in 2025 compensation, marking a hefty 75% spike from his first-year pay and solidifying the rising chief ...

That means that AbbVie investors are collecting 1.8 percentage points more yield than the broader market, and 1.2 percentage ...

AbbVie’s foray into the obesity space is successful so far, analysts agree, as amylin analog ABBV-295 elicited as much as 9.73% weight loss at 13 weeks in the multiple ascending dose portion of a ...

The two new facilities will create 300 jobs and are part of the drugmaker’s broader plan to invest $100 billion in the U.S.

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of tavapadon, from AbbVie.

Senators are probing which products fall under Medicaid-related deal provisions and whether any “MFN” prices are meaningfully lower than current Medicaid net prices after rebates.

AbbVie has a collection of drugs that produce substantial cash flow. The company has steadily rewarded investors with dividend growth. AbbVie's dividend yield is far above the market's, and the ...